Paper Details

  1. Home
  2. Paper Details

Long-term response to pimitespib in postoperative recurrent gastrointestinal stromal tumors with PDGFRA D842V mutation: a case report.

Author: DokiYuichiro, EguchiHidetoshi, KurokawaYukinori, MakinoTomoki, NakajimaKiyokazu, SaitoTakuro, TakahashiTsuyoshi, TanakaKoji, TeranishiRyugo, YamamotoKazuyoshi, YamashitaKotaro

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Exon 18 D842V is the most frequent mutation in Platelet-Derived Growth Factor Receptor alpha (PDGFRA)-mutated gastrointestinal stromal tumor (GIST). This report presents a case of a long-term response to pimitespib (PIMI), a novel heat shock protein 90 (HSP90) inhibitor, in GIST with PDGFRA D842V mutation.
Paper Details　
Original Abstract of the Article :
Exon 18 D842V, which is a point mutation from aspartic acid to valine at codon 842, is the most frequent mutation in Platelet-Derived Growth Factor Receptor alpha (PDGFRA)-mutated gastrointestinal stromal tumor (GIST). In the Japanese GIST guidelines, no standard systematic therapy is available for ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082137/

データ提供：米国国立医学図書館（NLM）

Long-Term Response to Pimitespib in Postoperative Recurrent Gastrointestinal Stromal Tumors with PDGFRA D842V Mutation: A Case Report

This study delves into the fascinating world of oncology, specifically addressing the challenges of treating recurrent gastrointestinal stromal tumors (GISTs). The researchers employed a case report methodology to investigate the efficacy of pimitespib (PIMI), a novel heat shock protein 90 (HSP90) inhibitor, in a patient with a specific mutation, PDGFRA D842V. This mutation is particularly prevalent in Japanese GIST patients, and the current guidelines lack a standardized treatment approach for this type of tumor after recurrence. The study's findings highlight the potential of PIMI as a promising treatment option for this challenging condition.

The Potential of Pimitespib in Treating Recurrent GIST

The study's results suggest that PIMI may offer a significant therapeutic benefit for GIST patients with the PDGFRA D842V mutation, providing hope for a more effective treatment strategy.

A Ray of Hope for GIST Patients

This case report brings a glimmer of hope for patients struggling with recurrent GIST. If further research confirms these findings, PIMI could offer a new avenue for treating this challenging disease.

Dr. Camel's Conclusion

The researchers have presented a captivating case report exploring the potential of PIMI for treating recurrent GIST with the PDGFRA D842V mutation. This research is like a refreshing oasis in the vast desert of GIST treatment, offering hope for a more effective approach.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-04-11
Further Info :

Pubmed ID

37027098

DOI: Digital Object Identifier

PMC10082137

Related Literature

Article Analysis
・Effects of avapritinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.